Literature DB >> 2361075

Inhibition of serum-enhanced HIV-1 infection of U937 monocytoid cells by recombinant soluble CD4 and anti-CD4 monoclonal antibody.

M Zeira1, R A Byrn, J E Groopman.   

Abstract

Mononuclear phagocytes can be infected with the human immunodeficiency virus type 1 (HIV-1). Although these cells express CD4 antigen, which is the recognized cellular receptor for HIV, additional cell surface proteins such as the Fc receptor, might serve as receptors for infection. In order to study this possibility we used the U937 monocytic cell line as a target for HIV infection. Flow cytometry of U937 showed that 97% of cells expressed CD4, 33% expressed the high affinity 72 kD Fc receptor (FcRI), and 74% expressed the low-affinity 40 kD Fc receptor (FcRII). Virus neutralization tests were performed by preincubating heat-inactivated human anti-HIV sera with HIV-1, IIIB strain, and then challenging U937. After 13 days in culture, productive HIV-1 infection was monitored by reverse transcriptase activity. High concentrations of certain sera (10(-1)-10(-3) dilutions) neutralized HIV-1, but at subneutralizing concentrations (10(-4)-10(-6) dilutions), five of these sera enhanced viral infection approximately two- to threefold. This enhancement of HIV-1 infection was totally blocked by 1 microgram/ml recombinant soluble CD4 (rCD4) or by 0.5 microgram/ml anti-CD4 Leu3a monoclonal antibody. These results suggest that serum enhancement of HIV-1 infection, thought to be due to binding to the monocyte Fc receptor, requires HIV-1 binding to CD4, since rCD4 or Leu3a blocked this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2361075     DOI: 10.1089/aid.1990.6.629

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages.

Authors:  P P Shadduck; J B Weinberg; A F Haney; J A Bartlett; A J Langlois; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus.

Authors:  D C Montefiori; M Murphey-Corb; R C Desrosiers; M D Daniel
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

4.  Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent.

Authors:  C A Jordan; B A Watkins; C Kufta; M Dubois-Dalcq
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.

Authors:  J Trial; H H Birdsall; J A Hallum; M L Crane; M C Rodriguez-Barradas; A L de Jong; B Krishnan; C E Lacke; C G Figdor; R D Rossen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

Review 7.  Fc gamma receptors in cancer and infectious disease.

Authors:  M W Fanger; D V Erbe
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

8.  Antibody-dependent enhancement of hepatitis C virus infection.

Authors:  Keith Meyer; Malika Ait-Goughoulte; Zhen-Yong Keck; Steven Foung; Ranjit Ray
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

9.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.

Authors:  J A Partaledis; K Yamaguchi; M Tisdale; E E Blair; C Falcione; B Maschera; R E Myers; S Pazhanisamy; O Futer; A B Cullinan
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro.

Authors:  F D Tóth; P Mosborg-Petersen; J Kiss; G Aboagye-Mathiesen; M Zdravkovic; H Hager; J Aranyosi; L Lampé; P Ebbesen
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.